850142-72-2

Basic information

• Product Name: 6-Bromo-2-fluoro-3-hydroxypyridine
• Synonyms: 6-Bromo-2-fluoro-3-hydroxypyridine;6-Bromo-2-fluoro-3-pyridinol
• CAS NO: 850142-72-2
• Molecular Formula: C5H3BrFNO
• Molecular Weight: 191.99
• Mol File: 850142-72-2.mol

Chemical Properties

• Boiling Point: 355 °C at 760 mmHg
• Flash Point: 168.5 °C
• Appearance: /
• Density: 1.891 g/cm³
• Vapor Pressure: 1.57E-05mmHg at 25°C
• Refractive Index: 1.582
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 4.46±0.10(Predicted)
• CAS DataBase Reference: 6-Bromo-2-fluoro-3-hydroxypyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-2-fluoro-3-hydroxypyridine(850142-72-2)
• EPA Substance Registry System: 6-Bromo-2-fluoro-3-hydroxypyridine(850142-72-2)

Safety Data

• Hazardous Substances Data: 850142-72-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Bromo-2-fluoro-3-hydroxypyridine is used as a building block in the synthesis of pharmaceuticals for its unique structural features, contributing to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 6-Bromo-2-fluoro-3-hydroxypyridine serves as a key intermediate in the production of agrochemicals, aiding in the creation of compounds that can enhance crop protection and yield.
Used in Organic Synthesis:
6-Bromo-2-fluoro-3-hydroxypyridine is utilized as a reagent in organic reactions, enabling the introduction of functional groups in organic molecules, which is crucial for the synthesis of a wide range of organic compounds with various applications across different industries.

InChI:InChI=1/C5H3BrFNO/c6-4-2-1-3(9)5(7)8-4/h1-2,9H

Upstream product

• 174669-74-0 2-fluoro-3-hydroxypyridine 

Downstream Products

• 1438286-73-7 2-fluoro-3-methoxy-6-(1-(3,4,5-trimethoxyphenyl)vinyl)pyridine 
• 850142-73-3 6-bromo-2-fluoro-3-methoxypyridine 

Relevant articles and documents

COMT INHIBITING METHODS AND COMPOSITIONS

Compounds that inhibit COMT enzyme and pharmaceutical compositions comprising the same are provided herein. Methods of treating various psychiatric and neurological disorders with the compounds and pharmaceutical compositions described herein are also provided.

N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B

The present invention relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I where R1, R2, L1, L2, X, Y, and Y' are described t

SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B

Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed. Such diseases include, without limitation, neurological dysfunction such as Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, and seizure disorders; emotional disorders; depression; bipolar disorder; obsessive-compulsive disorder; and other anxiety disorders.

BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS

The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.

OXAZOLOBENZIMIDAZOLE DERIVATIVES

The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

1-‘2-(4-HYDROXYPHENYL)-2-HYDROXYETHYL!-PIPERIDIN-4-OL COMPOUNDS AS NMDA RECEPTOR ANTAGONISTS

This invention provides a compound of the formula (I), wherein R1 and R2 independently represents a hydrogen atom or the like; R3 represents an aryl group having from 6 to 10 ring carbon or the like; said aryl groups havin

FUSED LACTAM COMPOUNDS

This invention provides a compound the formula (I), wherein R1 represents an aryl group having from 6 to 10 ring carbon atoms etc.; R2 represents a hydrogen atom etc., n epresents 0, 1 or 2; said heteroaryl group is unsubstituted or